Ozempic & Thyroid Cancer Risk: Evidence & Safety Overview

Last reviewed: May 31, 2026

Last updated: May 31, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Current clinical evidence does not establish that Ozempic (semaglutide) directly causes thyroid cancer in humans. The FDA has not issued a causal warning, though rodent studies from the drug's development phase identified thyroid C-cell tumors in mice and rats at high doses—findings that do not automatically translate to human risk.

For patients considering GLP-1 receptor agonists like semaglutide or tirzepatide, understanding your individual thyroid health baseline and any family history of thyroid disease is critical. PlexusDx supports precision wellness by helping you evaluate medical eligibility and discuss risk factors with your provider before starting treatment.

What the Preclinical Data Actually Shows

During drug development, semaglutide was tested in rodent safety studies. Mice and rats receiving semaglutide at doses many times higher than human therapeutic doses developed C-cell hyperplasia and medullary thyroid carcinoma (a rare thyroid cancer subtype). These findings prompted the FDA to include thyroid warnings in the prescribing information.

Rodent models do not always predict human outcomes. Species differences in thyroid physiology, dose scaling, and drug metabolism mean that animal tumor findings require careful interpretation. The FDA's decision to include the warning reflects a precautionary approach, not confirmed human risk.

Human Clinical Evidence and Real-World Safety Data

Across multiple large randomized controlled trials (SUSTAIN 1-7 for semaglutide, SURPASS trials for tirzepatide), thyroid cancer incidence was not elevated in GLP-1 treatment groups compared to placebo. Post-marketing surveillance and pharmacovigilance databases have not identified a significant thyroid cancer signal in the millions of patients using these medications.

Long-term follow-up data continues to accumulate. Current evidence supports the safety profile for most patients, though individuals with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should not use GLP-1 receptor agonists due to the preclinical warning.

Data Source	Key Finding	Patient Population	Implication
SUSTAIN RCTs (semaglutide)	No increased thyroid cancer incidence vs. placebo	2,000+ patients over 1-2 years	Supports safety in general population
SURPASS RCTs (tirzepatide)	Thyroid malignancy rate similar to placebo arms	4,000+ patients with diabetes	Comparable safety profile to semaglutide
FDA Adverse Event Reports	No emerging thyroid cancer cluster	Millions of doses dispensed (2021-2024)	Post-market surveillance shows no signal
Preclinical Studies	C-cell tumors in rodents at high doses	Mice and rats only, not human-equivalent doses	Warrants monitoring but does not confirm human risk

Thyroid Baseline Assessment and Individual Risk Stratification

Before starting any GLP-1 medication, a complete baseline thyroid evaluation supports informed decision-making. This typically includes serum thyroid-stimulating hormone (TSH), free thyroxine (T4), and thyroid peroxidase antibodies if autoimmune thyroid disease is suspected. Existing thyroid nodules or abnormalities on imaging should be documented.

Family history of medullary thyroid cancer or MEN2 syndrome represents a contraindication to GLP-1 use. Patients with a personal history of thyroid cancer (differentiated types) may be candidates with close provider oversight and endocrinology consultation. The goal is to identify who can safely benefit and who requires alternative approaches.

Who Should and Should Not Use GLP-1 Receptor Agonists

GLP-1 medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma, or those with confirmed MEN2 syndrome. Additionally, anyone with an active thyroid malignancy or unexplained thyroid nodule requiring biopsy should not initiate therapy without endocrinology input and diagnostic resolution.

Most patients without these contraindications can use GLP-1 receptor agonists safely, provided baseline thyroid status is assessed and documented. Ongoing monitoring includes symptom awareness and periodic TSH checks as recommended by your provider. A collaborative conversation with your healthcare team clarifies whether treatment is appropriate for your health profile.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context about predispositions in GLP-1 receptor and metabolic pathways, including variants like GLP1R rs6923761 and MC4R rs17782313. While the test does not assess thyroid cancer risk directly, understanding your genetic profile in peptide metabolism and glucose regulation can support a more complete eligibility and response assessment with your provider.

The genetic test reveals whether you carry variants associated with differential GLP-1 receptor signaling and metabolic response. This information, combined with your baseline thyroid biomarkers (TSH, free T4, thyroid antibodies) and personal/family thyroid history, can support a more informed conversation about whether compounded GLP-1 options are right for you. Genetic predisposition does not predict exact medication response and should be interpreted with your qualified healthcare provider.

By integrating genetic insights with comprehensive medical history and thyroid baseline assessment, you and your provider can make a more personalized decision about GLP-1 suitability. PlexusDx compounded semaglutide and tirzepatide options become part of a medically tailored plan only after this evaluation is complete.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Oral starts at from $209/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.